Hommel E, Faber J, Kirkegaard C, Siersbaek-Nielsen K, Friis T
Horm Metab Res. 1985 Feb;17(2):90-2. doi: 10.1055/s-2007-1013459.
A radioimmunoassay for the estimation of 3,5-diiodothyronine (3,5-T2) in human urine has been established. The urinary excretion of both glucuronide and sulfate conjugates of 3,5-T2 were estimated after enzymatic deconjugation. In 19 healthy controls the median excretion of unconjugated 3,5-T2 was 276 pmol/d, whereas the median excretion of glucuronidated and sulfated 3,5-T2 in 7 healthy subjects was 448 and 451 pmol/d, respectively. The median excretion of 154 pmol/d in 9 hypothyroid patients did not differ from that found in controls. In contrast 12 patients with hyperthyroidism had an enhanced excretion, 1312 pmol/d (P less than 0.01). Compared with previous data on the daily degradation of 3,5-T2, it is concluded that approximately one-sixth of degradated 3,5-T2 is excreted in the urine.
已建立一种用于测定人尿中3,5 - 二碘甲状腺原氨酸(3,5 - T2)的放射免疫分析方法。在酶促去结合后,对3,5 - T2的葡糖醛酸和硫酸盐结合物的尿排泄量进行了估算。在19名健康对照者中,未结合的3,5 - T2的排泄中位数为276 pmol/d,而在7名健康受试者中,3,5 - T2葡糖醛酸化和硫酸化产物的排泄中位数分别为448和451 pmol/d。9名甲状腺功能减退患者的排泄中位数为154 pmol/d,与对照组无差异。相比之下,12名甲状腺功能亢进患者的排泄量增加,为1312 pmol/d(P<0.01)。与先前关于3,5 - T2每日降解的数据相比,得出的结论是,约六分之一降解的3,5 - T2经尿液排泄。